Skip Navigation


JAC Advance Access originally published online on April 6, 2005
Journal of Antimicrobial Chemotherapy 2005 55(5):608-611; doi:10.1093/jac/dki095
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/5/608    most recent
dki095v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zoulim, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zoulim, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions{at}oupjournals.org

Leading article

Combination of nucleoside analogues in the treatment of chronic hepatitis B virus infection: lesson from experimental models

Fabien Zoulim*

INSERM U271, 151 Cours Albert Thomas, 69003 Lyon, France

* Tel: +33-4-72-68-19-70; Fax: +33-4-72-68-19-71; Email: zoulim{at}lyon.inserm.fr

Owing to the persistence of hepatitis B virus (HBV) and the selection of drug-resistant mutants, a new concept of antiviral therapy for chronic hepatitis B relies on the combination of nucleoside analogues. In experimental models of HBV infection, several key points concerning these combinations were addressed. (i) Is it possible to achieve a synergic antiviral effect with polymerase inhibitors? (ii) Is it possible to impact on intracellular viral covalently closed circular DNA? (iii) What is the impact of the cross-resistance patterns of the different nucleoside analogues? (iv) What is the effect of viral load suppression on the restoration of specific antiviral cellular responses? The clinical impact of these key issues is discussed in the perspective of new clinical trials.

Keywords: HBV , antiviral , therapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Therapeutic Advances in GastroenterologyHome page
D. T.-Y. Lau and W. Bleibel
Review: Current status of antiviral therapy for hepatitis B
Therapeutic Advances in Gastroenterology, July 1, 2008; 1(1): 61 - 75.
[Abstract] [PDF]

Home page
 J. Virol.Home page
W. Gao and J. Hu
Formation of Hepatitis B Virus Covalently Closed Circular DNA: Removal of Genome-Linked Protein
J. Virol., June 15, 2007; 81(12): 6164 - 6174.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
C. Osiowy, J.-P. Villeneuve, E. J. Heathcote, E. Giles, and J. Borlang
Detection of rtN236T and rtA181V/T Mutations Associated with Resistance to Adefovir Dipivoxil in Samples from Patients with Chronic Hepatitis B Virus Infection by the INNO-LiPA HBV DR Line Probe Assay (Version 2).
J. Clin. Microbiol., June 1, 2006; 44(6): 1994 - 1997.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.